ARTICLE | Company News
U.K. firm licenses trial success prediction tool from Molecular Health
January 11, 2019 6:31 PM UTC
Daten Capital LLP (London, U.K.) received exclusive rights from Molecular Health (Heidelberg, Germany) to Molecular Health Predict (MH Predict), an AI-based tool to predict the outcome of clinical trials, for use in the financial industry.
Molecular Health will receive an undisclosed annual license fee, plus success-based payments...